Lightnews — Scholar-powered news

Larger trials needed to prove Tylenol, Autism risk correlation: Dr. Scott Gottlieb

www.youtube.com

1 8 24

Scott Gottlieb, MD @scottgottliebmd.bsky.social · 15d

My hit on @cnbc.com today on the new actions to address autism and the need to exercise more judgment and caution

youtu.be/B7t9ryBoBfQ

Measles Death Shows How Virus Can Hide in the Brain for Years

6 8 32

Reposted by Scott Gottlieb, MD

Dorit Reiss @doritreiss.bsky.social · 17d

Measles Death Shows How Virus Can Hide in the Brain for Years www.aol.com/articles/mea...

A school-aged child in Los Angeles County has died from a rare but always fatal complication from a measles infection they acquired when they were an infant who was too young to be vaccinated. Expert...

www.aol.com

1 22 66

Scott Gottlieb, MD @scottgottliebmd.bsky.social · 22d

My appearance on #CNBC today about the #CDC’s #ACIP meeting on vaccines, which could bring action by HHS to remove the MMRV vaccine, eliminate the recommendation for Hep B in newborns, and narrow use of Covid vaccines.

CDC vaccine panel to meet this week: Here's what's at stake

Dr. Scott Gottlieb reacts to RFK Jr. linking autism to Tylenol

www.youtube.com

7 17 43

Reposted by Scott Gottlieb, MD

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Sep 8

My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+

We risk a return of communicable diseases in children.

www.youtube.com/watch?v=00cI...

2 33 73

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Sep 8

My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+

We risk a return of communicable diseases in children.

www.youtube.com/watch?v=00cI...

2 33 73

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Sep 8

My segment from Friday in @cnbc.com on vaccine policy

youtu.be/J9FVvNR-n_E

Securing America’s Pharmaceutical Innovation Edge

2 16 40

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Sep 8

I’ll be coming up on @SquawkCNBC at 6:30 to discuss vaccine safety and public health.

1 22

Reposted by Scott Gottlieb, MD

USC Schaeffer @schaeffer.usc.edu · Aug 20

📅 Join us Sept. 19 for a conference on #FDA policy reforms aimed at reducing drug development costs and getting valuable new treatments to patients faster.

Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more

➡️Registration: schaeffer.usc.edu/event/reform...

Reforming the FDA to Meet Today's Innovation Challenges
Friday, Sept. 19, 9-11 am ET
USC Capital Campus
Hosted by USC Schaeffer

1 4

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Aug 21

My editorial in JAMA Health Forum: To support the academic research enterprise, we should pursue regulatory reforms that enable institutions to advance more of their discoveries to patients and, in doing so, capture more economic value of innovations they achieve

jamanetwork.com/journals/jam...

This JAMA Forum discusses challenges to the US’s standing as a global leader in biomedical innovation from China, in the context of recent reductions in funding for biomedical research by the federal ...

jamanetwork.com

3 11

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Aug 19

CSL, a major manufacturer of flu vaccine, is spinning off its entire vaccine unit and cutting up to 15% of its staff. Influenza vaccine uptake is off by about 10%

www.wsj.com/business/csl...

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure

Australia-listed CSL, which has a significant portion of its business in the U.S., announced its intention to simplify its operating structure amid a challenging and volatile environment.

www.wsj.com

2 10 26

Reposted by Scott Gottlieb, MD

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jul 26

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited

The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

insights.citeline.com

2 25 44

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jul 26

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited

The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

insights.citeline.com

2 25 44

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jul 26

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers

insights.citeline.com/pink-sheet/a...

5 68 96

Reposted by Scott Gottlieb, MD

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jun 30

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel

YouTube video by Face the Nation

Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel

6 28 94

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jun 30

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

YouTube video by Face the Nation

Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years

6 28 94

Reposted by Scott Gottlieb, MD

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jun 26

My segment today on cnbc.com on the CDC’s ACIP meeting.

Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years

5 28 72

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jun 26

My segment today on cnbc.com on the CDC’s ACIP meeting.

Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements

5 28 72

Reposted by Scott Gottlieb, MD

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jun 1

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

4 28 88

Scott Gottlieb, MD @scottgottliebmd.bsky.social · Jun 1

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

4 28 88

Reposted by Scott Gottlieb, MD

Scott Gottlieb, MD @scottgottliebmd.bsky.social · May 29

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.

Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements

1 29 85

Scott Gottlieb, MD @scottgottliebmd.bsky.social · May 29

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.

How to stop the shift of drug discovery from the U.S. to China

1 29 85

Reposted by Scott Gottlieb, MD

Scott Gottlieb, MD @scottgottliebmd.bsky.social · May 6

My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

How to stop the shift of drug discovery from the U.S. to China

2 16 50

Reposted by Scott Gottlieb, MD

Gregory Riely @rielymd.bsky.social · May 6

How to stop the shift of drug discovery from the U.S. to China www.statnews.com/2025/05/06/h... from @scottgottliebmd.bsky.social via @statnews.com

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.